Related Experiment Video
Updated: Feb 11, 2026

The Cultivation, Growth, and Viability of Lactic Acid Bacteria: A Quality Control Perspective
Published on: June 16, 2022
Efficacy and Safety of Poly-L-lactic Acid for Midface Rejuvenation: A 12-Month Split-face Controlled Evaluation With
Background:
Poly-L-lactic acid (PLLA) is a biostimulatory injectable that restores midfacial volume through collagen neogenesis rather than gel-based filling. Controlled clinical evidence directly quantifying PLLA's volumetric efficacy remains limited.
Objectives:
To evaluate the efficacy, safety, and patient-reported outcomes of a Norberg Medical PLLA formulation for midface rejuvenation in a prospective, evaluator-blinded, split-face controlled study. Participants were enrolled between July 2024 and September 2024, with follow-up completed in September 2025.
Methods:
Ninety-five patients underwent three standardized PLLA sessions on one hemiface and saline placebo on the contralateral side. Each vial contained 150 mg PLLA in spherical microparticles, reconstituted with 5 mL sterile water without lidocaine. Assessments included Wrinkle Severity Rating Scale (WSRS), Vectra H1 3D volumetry (malar, zygomatic, mandibular), FACE-Q, and Global Aesthetic Improvement Scale (GAIS). Two blinded evaluators rated WSRS. Statistical analysis included paired testing, responder rates (≥1-grade WSRS improvement), and inter-rater reliability (ICC).
Results:
At 12 months, PLLA-treated sides showed significant WSRS reduction vs baseline and saline control (Δ = -0.68, P < .001). 3D analysis confirmed sustained volumetric enhancement across all midface subunits. Inter-rater reliability was excellent (ICC = 0.91), and 82.1% achieved ≥1-grade WSRS improvement. Patient satisfaction remained high, mirroring objective findings. Adverse events were mild and transient, with no granulomas, nodules, or vascular events recorded.
Conclusions:
Controlled split-face evaluation demonstrated that standardized PLLA treatment yields measurable, long-lasting midfacial volume restoration with excellent safety and high patient satisfaction. No granulomas or delayed-onset nodules were observed in this 12-month, 95-patient cohort, supporting a favorable safety profile for this PLLA formulation under these study conditions.
Level Of Evidence: 2 (Therapeutic):
For image description, please refer to the figure legend and surrounding text.
Related Concept Videos
Survey Safety
Data Reporting and Recording
Self-Efficacy
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
¹H NMR: Complex Splitting
Splitting diagrams or splitting tree diagrams are routinely used to depict such complex couplings. While drawing splitting diagrams, the splitting with the larger coupling constant is usually applied...

